Ovid Therapeutics (NASDAQ: OVID) has expanded its Scientific Advisory Board (SAB) with the appointment of leading neurologists, neuroscientists, and epileptologists. The expanded SAB will advise on the potential application of Ovid’s…
[ad_2]
Source link
